Brentuximab Vedotin + Pembrolizumab
Phase 2WithdrawnDevelopment Stage
Recurrent Angioimmunoblastic T-Cell Lymphoma
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
Mar 1, 2020 → Mar 1, 2029
About Brentuximab Vedotin + Pembrolizumab
Brentuximab Vedotin + Pembrolizumab is a phase 2 stage product being developed by Merck for Recurrent Angioimmunoblastic T-Cell Lymphoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04795869. Target conditions include Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Angioimmunoblastic T-Cell Lymphoma were approved
Hype Score Breakdown
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05313243 | Phase 2 | Recruiting |
| NCT04609566 | Phase 2 | Completed |
| NCT04795869 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Recurrent Angioimmunoblastic T-Cell Lymphoma